MX2022010663A - Variantes de alfa-galactosidasa humana. - Google Patents

Variantes de alfa-galactosidasa humana.

Info

Publication number
MX2022010663A
MX2022010663A MX2022010663A MX2022010663A MX2022010663A MX 2022010663 A MX2022010663 A MX 2022010663A MX 2022010663 A MX2022010663 A MX 2022010663A MX 2022010663 A MX2022010663 A MX 2022010663A MX 2022010663 A MX2022010663 A MX 2022010663A
Authority
MX
Mexico
Prior art keywords
human alpha
galactosidase
engineered human
compositions
galactosidase polypeptides
Prior art date
Application number
MX2022010663A
Other languages
English (en)
Inventor
Nikki Dellas
Judy Victoria Antonio Viduya
Jonathan Vroom
William Casey Hallows
Adam P Silverman
Antoinette Sero
Kristen Jean Vallieu
Yu Zhu
Chinping Chng
Rachel Cathleen Botham
Ismaili Moulay Hicham Alaoui
David William Homan
Kerryn Mccluskie
Charu Shukla Reddy
Original Assignee
Codexis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Codexis Inc filed Critical Codexis Inc
Publication of MX2022010663A publication Critical patent/MX2022010663A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022—Alpha-galactosidase (3.2.1.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención proporciona polipéptidos de alfa-galactosidasa humana diseñados y composiciones de los mismos; los polipéptidos de alfa-galactosidasa humana diseñados han sido optimizados para proporcionar termoestabilidad mejorada, estabilidad sérica, captación celular mejorada, estabilidad tanto bajo condiciones ácidas (pH <4) como básicas (pH >7), inmunogenicidad reducida, y eliminación mejorada de globotriaosilceramida de las células; la invención también se refiere al uso de las composiciones que comprenden los polipéptidos de alfa-galactosidasa humana diseñados para fines terapéuticos.
MX2022010663A 2020-02-28 2021-02-26 Variantes de alfa-galactosidasa humana. MX2022010663A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062982949P 2020-02-28 2020-02-28
PCT/US2021/019811 WO2021173928A2 (en) 2020-02-28 2021-02-26 Human alpha-galactosidase variants

Publications (1)

Publication Number Publication Date
MX2022010663A true MX2022010663A (es) 2022-09-23

Family

ID=77463498

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022010663A MX2022010663A (es) 2020-02-28 2021-02-26 Variantes de alfa-galactosidasa humana.

Country Status (17)

Country Link
US (1) US20210269787A1 (es)
EP (1) EP4110926A2 (es)
JP (1) JP2023516301A (es)
KR (1) KR20220146601A (es)
CN (1) CN116096898A (es)
AR (1) AR121457A1 (es)
AU (1) AU2021228689A1 (es)
BR (1) BR112022016990A2 (es)
CA (1) CA3173294A1 (es)
CL (1) CL2022002330A1 (es)
CO (1) CO2022012809A2 (es)
EC (1) ECSP22075305A (es)
IL (1) IL295818A (es)
MX (1) MX2022010663A (es)
PE (1) PE20230487A1 (es)
TW (1) TW202146648A (es)
WO (1) WO2021173928A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3898960A4 (en) 2018-12-20 2022-11-30 Codexis, Inc. VARIANTS OF HUMAN ALPHA GALACTOSIDASE
WO2024042485A1 (en) * 2022-08-25 2024-02-29 Takeda Pharmaceutical Company Limited Composition for use in the treatment of fabry disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2361631A1 (en) * 2002-04-25 2011-08-31 Shire Human Genetic Therapies, Inc. Treatment of alpha-galactosidase a deficiency
US9194011B2 (en) * 2009-11-17 2015-11-24 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
EP4234699A1 (en) * 2014-12-22 2023-08-30 Codexis, Inc. Human alpha-galactosidase variants
AU2020327019A1 (en) * 2019-08-07 2022-03-03 Amicus Therapeutics, Inc. Methods of treating Fabry disease in patients having a mutation in the GLA gene

Also Published As

Publication number Publication date
TW202146648A (zh) 2021-12-16
JP2023516301A (ja) 2023-04-19
BR112022016990A2 (pt) 2022-10-25
KR20220146601A (ko) 2022-11-01
PE20230487A1 (es) 2023-03-21
EP4110926A2 (en) 2023-01-04
CA3173294A1 (en) 2021-09-02
CO2022012809A2 (es) 2022-09-20
IL295818A (en) 2022-10-01
WO2021173928A3 (en) 2021-09-30
AR121457A1 (es) 2022-06-08
CN116096898A (zh) 2023-05-09
AU2021228689A1 (en) 2022-09-01
US20210269787A1 (en) 2021-09-02
ECSP22075305A (es) 2022-12-30
CL2022002330A1 (es) 2023-03-03
WO2021173928A2 (en) 2021-09-02

Similar Documents

Publication Publication Date Title
PH12021551372A1 (en) Human alpha-galactosidase variants
MX2022010663A (es) Variantes de alfa-galactosidasa humana.
MX2021014007A (es) Proteinas de union a epcam y metodos de uso.
IN2015DN02553A (es)
IN2012DN03824A (es)
TW200510306A (en) Novel hydroxyindoles, their use as inhibitors of phosphodiesterase 4, and processes for preparing them
NZ603348A (en) Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
MX2011013183A (es) Polipeptidos de la hormona de crecimiento y metodos de preparacion y su uso.
IL226857A (en) Recombinant proteins that underwent glycosylation at site n correspond to prokaryotes
SG196821A1 (en) New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein
MX2022010175A (es) Proteinas de union a flt3 y metodos de uso.
MX2009002816A (es) Proteinas de fusion de albumina.
PL356846A1 (en) Use of interleukin-6 antagonists for the treatment of diseases characterised by high levels of aromatase
MX2009008270A (es) Polipeptido novedoso que tiene actividad anti-tumoral.
RU2013151875A (ru) Модифицированная кислая альфа глюкозидаза с ускоренным процессингом
MX2021000328A (es) Enzimas de variantes de galactosa oxidasa modificadas geneticamente.
MX2010000410A (es) Termoestabilizacion de proteinas.
NZ614557A (en) Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use
PL1951283T3 (pl) Kompozycje farmaceutyczne do leczenia i zapobiegania rakowi jajnika
MX2022004345A (es) Construcciones de igf2 variantes.
WO2021216687A9 (en) Peptides for the treatment of covid-19
MX2023002421A (es) Variantes de amilasa modificadas geneticamente.
WO2017062666A3 (en) Enzyme replacement therapy for mucopolysaccharidosis iiid
MX2022007399A (es) Variantes de alfa-glucosidasa ácida diseñadas.
EP1282641A4 (en) Cervical cancer suppressing protein in women, polynucleotide encoding it, cell transformed by polynucleotide, and method of suppressing proliferation of cancer cells using the expression vector